Objectives: Ethanol is bactericidal against most pathogens implicated in central line-associated bloodstream infections (CLABSIs) and biofilms. Current Infectious Diseases Society of America guidelines cite insufficient evidence to support adjunctive ethanol-lock therapy (ELT) for central venous catheter (CVC) salvage in patients with CLABSI in combination with systemic antimicrobial treatment. We evaluated the safety and potential efficacy of 70% ELT for CLABSI at our institution after implementation of a hospital ELT protocol.
Methods: We collected data on all patients treated with adjunctive 70% ELT for catheter salvage from September 2009 to September 2011 and assessed clinical outcomes and adverse events associated with ELT.
Results: Sixty-eight hospitalized patients received 70% ELT for CVC salvage: 45 (66%) met the criteria for CLABSI. Five (11%) had persistent or recurrent bacteraemia triggering CVC removal; 28 (62%) preserved their CVC long term. There were no documented adverse events associated with ELT.
Discussion: Adjunctive 70% ELT is an inexpensive, well-tolerated option for CVC salvage in patients with CLABSI and warrants further investigation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019330 | PMC |
| http://dx.doi.org/10.1093/jac/dku017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing Breast Cancer Detection: A Machine Learning Approach Using Multielectrode Bioimpedance.
Bioelectricity
December 2024
Department of Electrical Engineering and Industrial Computing, Ecole Nationale Supérieure des Technologies Avancées, Algiers, Algeria.
Background: Early detection of cancerous tumors is a critical factor in improving treatment outcomes. To address this need, this study explores a simple, effective, and cost-efficient method for early cancer detection by measuring the bioimpedance of living tissues. Bioimpedance-based methods hold significant promise for the early detection of cancerous tumors.
View Article and Find Full Text PDFBiopeptide-rich fermented hemp seeds: Boosting anti-inflammatory and immune responses through Lactiplantibacillus plantarum probiotic fermentation.
Int J Biol Macromol
December 2024
Department of Food Science and Biotechnology, College of Agriculture and Life Sciences, Kangwon National University, Chuncheon, 24341, South Korea; Future F Biotech Co., Ltd, Chuncheon 24341, South Korea. Electronic address:
Article Synopsis
- Hemp seeds are shown to have anti-inflammatory and immunological benefits, and fermentation with Lactiplantibacillus plantarum enhances these properties.
- The study found that fermented hemp seed extracts significantly inhibited inflammatory cytokines more effectively than unfermented seeds, indicating a boost of 25% to 39.3% in their effects.
- Metabolomic analysis identified novel bioactive compounds linked to these enhanced effects, suggesting fermented hemp seeds could be developed into functional food ingredients for health and wellness applications.
Feasibility and effectiveness of the prolonged use of eltrombopag in addition to immunosuppression in patients with acquired aplastic anemia: a single-center real-life experience.
Platelets
December 2024
Hematology and Transplantation Unit, IRCCS San Gerardo Hospital, Monza, Italy.
Acquired Aplastic Anemia (AAA) is a rare disease involving primary bone marrow failure with consequent pancytopenia. The addition of the synthetic thrombopoietin-receptor agonist eltrombopag (ELT) to standard immunosuppression for the treatment of AAA has led to improvements in hemopoietic outcomes of AAA. Most of the data on the use of ELT for AAA was based on a maximum of 6 months of therapy.
View Article and Find Full Text PDFPurpose: MammaPrint (MP) determines distant metastatic risk and may improve patient selection for extended endocrine therapy (EET). This study examined MP in predicting extended letrozole therapy (ELT) benefit in patients with early-stage breast cancer (BC) from the NSABP B-42 trial.
Patients And Methods: MP was tested in 1,866 patients randomly assigned to receive ELT or placebo.
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.
Clin Cancer Res
May 2024
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
Article Synopsis
- The study examined the Breast Cancer Index (BCI) to predict benefits from extended endocrine therapy (EET) in hormone receptor-positive breast cancer patients participating in the NSABP B-42 trial.
- A total of 2,178 patients were analyzed, finding minimal overall RFI benefit from extended letrozole therapy, with no significant interaction between BCI levels and treatment outcome.
- However, after four years, patients with high BCI (H/I) showed significant benefits from EET, particularly in the HER2-negative subgroup, suggesting BCI's potential as a predictive marker for future studies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!